Related Experiment Video

Updated: Jun 30, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Normalizing NADPH oxidase contributes to attenuating diabetic nephropathy by the dual endothelin receptor antagonist

Ming Xu1, De-Zai Dai, Yin Dai

  • 1Research Division of Pharmacology, China Pharmaceutical University, Nanjing, China.

American Journal of Nephrology
|September 20, 2008
PubMed
Abstract

Insights

CPU0213, a dual endothelin receptor antagonist, effectively treated diabetic nephropathy (DN) by suppressing NADPH oxidase (NOX). This dual action normalized renal function in diabetic rats, highlighting a novel therapeutic approach for DN.

Area of Science:

  • Nephrology
  • Pharmacology
  • Oxidative Stress Research

Background:

  • Diabetic nephropathy (DN) is characterized by increased reactive oxygen species (ROS) primarily generated by NADPH oxidase (NOX).
  • The endothelin (ET) system, via endothelin A (ET(A)R) and B receptors (ET(B)R), can activate NOX, contributing to DN pathogenesis.
  • CPU0213 is a dual ET receptor antagonist designed to inhibit NOX and potentially attenuate DN.

Purpose of the Study:

  • To investigate the efficacy of CPU0213, a dual endothelin receptor antagonist, in mitigating diabetic nephropathy (DN).
  • To determine if CPU0213 suppresses NADPH oxidase (NOX) activity and associated oxidative stress in a rat model of DN.
  • To evaluate the impact of CPU0213 on renal function and markers of kidney damage in diabetic rats.

Main Methods:

  • A streptozotocin (STZ)-induced rat model of diabetes was established, with CPU0213 treatment administered during the final 4 weeks.
  • Rat mesangial cells (MCs) were exposed to high glucose conditions (30 mM) for 48 hours, with or without CPU0213 or NOX inhibitors (apocynin, diphenyleneiodonium).
  • Renal function, oxidative stress markers, NOX subunit expression, and ET system components were assessed in vivo and in vitro.

Main Results:

  • STZ-induced diabetic rats exhibited impaired renal function, elevated oxidative stress, and increased kidney weight index after 8 weeks.
  • Upregulation of NOX subunits and the ET system was observed in diabetic rats and high-glucose-treated MCs.
  • CPU0213 significantly suppressed these DN-associated abnormalities, including NOX and ET system upregulation, without affecting blood glucose levels.

Conclusions:

  • The endothelin (ET) pathway and NADPH oxidase (NOX) are concurrently upregulated in diabetic nephropathy (DN) pathogenesis.
  • CPU0213, a dual ET(A)R and ET(B)R antagonist, effectively normalized renal function in a rat model of DN.
  • Suppression of NOX by CPU0213 is a key mechanism underlying its renoprotective effects in DN.

More Related Videos

Preparation of Naringenin Solution for In Vivo Application08:18

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...